By: T. Feys MBA, MSc
About half of the adult patients with acute B-cell lymphoblastic leukemia (B-ALL) who do not achieve a molecular complete remission or who subsequently relapse cannot be cured with the current chemotherapy or targeted agents. In recent years, however, we have witnessed the emergence of different immune-based therapies in this setting. This includes monoclonal antibodies, bispecific T-cell engagers (BiTEs), antibodydrug conjugates (ADCs), and chimeric antigen receptor T-cells (CARs).
* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)
** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)
Top
